Browsing tag:

Sirolimus


As an immunosuppressant drug used to prevent transplant rejection, Sirolimus, CAS number 53123-88-9, is a macrolide. Particularly useful for kidney transplant patients, sirolimus is also known as the brand name Rapamune, which is marketed by Pfizer. The first patent for Rapamune is set to expire in October 2012. An addtional patent will expire in July[…]

Read More

Tacrolimus, CAS number 104987-11-3, was the second macrolide immunosuppressant discovered, second only to discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975. Discovered in 1984, tacrolimus, also known as FK-506 or Fujimycin, is an immunosuppressant drug, often given to organ transplant recipients. Tacrolimus is effective in helping to prevent transplant patients from experiencing[…]

Read More

For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]

Read More